This compound is primarily used in the development of novel antibiotics, particularly targeting drug-resistant bacterial infections. Its structure is optimized to inhibit bacterial protein synthesis, making it effective against a range of Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). It is also studied for its potential in treating tuberculosis, especially strains resistant to conventional therapies. Additionally, its unique mechanism of action reduces the likelihood of cross-resistance with existing antibiotics, enhancing its therapeutic value. Research is ongoing to explore its efficacy in combination therapies and its application in treating other bacterial infections.